Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims

- 1 67. (Canceled)
- 68. (Previously Amended) A method of alleviating a symptom of ocular inflammation associated with dry eye syndrome, comprising administering to a subject suffering from or at risk of developing dry eye syndrome an ocular protective combination (OPC) composition comprising a carotenoid and a polyphenol, wherein said carotenoid comprises astaxanthin and wherein said polyphenol comprises curcuma longa root powder, green tea, grape seed extract, or a citrus bioflavonoid, and co-administering to said subject a composition comprising an omega-3 fatty acid selected from the group consisting of eicosapentaenoic acid or docosahexaenoic acid, thereby alleviating said symptom of said dry eye syndrome.
- (Previously Presented) The method of claim 68, wherein said composition further comprises a glutathione precursor.
- (Previously Presented) The method of claim 68, wherein said composition further comprises a vitamin anti-oxidant.
- (Previously Presented) The method of claim 68, wherein said composition further comprises an alpha lipoic acid.
- (Previously Presented) The method of claim 68, wherein said method does not comprise beta-carotene.
- 73. (Previously Presented) The method of claim 68, wherein said omega-3 fatty acid

- is eicosapentaenoic acid or docosahexaenoic acid.
- (Previously Amended) The method of claim 68, wherein said carotenoid further comprises a mixed carotenoid compound or a zeaxanthin.
- 75. (Canceled)
- (Previously Amended) The method of claim 68, wherein said polyphenol further comprises a cox-2 inhibitor.
- (Previously Presented) The method of claim 76, wherein said cox-2 inhibitor is a
 quercetin, a bilberry extract, a hops PE, blueberry powder or tart cherry powder.
- (Previously Presented) The method of claim 69, wherein said glutathione precursor is taurine or N-acetyl-L-cysteine.
- (Previously Presented) The method of claim 70, wherein said vitamin anti-oxidant Vitamin A, Vitamin B, Vitamin C, Vitamin D or Vitamin E.
- (Previously Presented) The method of claim 68, wherein said composition further comprises a trace mineral.
- (Previously Presented) The method of claim 68, wherein said composition is administered systemically.
- (Previously Presented) The method of claim 68, wherein said composition is administered orally.
- (Previously Presented) The method of claim 68, wherein said composition is administered by directly contacting an ocular tissue.
- 84-106. (Canceled)

- 107. (Previously Amended) The method of claim 68, wherein said OPC composition does not comprise beta-carotene.
- 108. (Previously Amended) A method of alleviating a symptom of ocular inflammation associated with dry eye syndrome, comprising administering to a subject suffering from or at risk of developing dry eye syndrome an ocular protective combination (OPC) composition comprising

Vitamin A

Vitamin C

Vitamin D

Vitamin E

Vitamin K Thiamin

Iniamin

Riboflavin

Niacin

Vitamin B6

Folate

Vitamin B12

Pantothenic Acid

Biotin

Choline

Chromium

Copper

Iodine

Magnesium

Manganese

Selenium

Zinc

Alpha Lipoic Acid

Green Tea

Bilberry Extract

Blueberry Powder

Ginkgo biloba

Hops

Ouercetin

Tocotrienol Complex

Grape Seed Extract

Citrus Bioflavonoids

Taurine

N-Acetyl-L-Cysteine

Curcuma Ionga Root Powder

Zeaxanthin Astaxanthin Mixed Carotenoids Trace Minerals, and Tart Cherry Powder.

Vitamin A Vitamin C

109. (Previously Amended) A method of alleviating a symptom of ocular inflammation associated with dry eye syndrome, comprising administering to a subject suffering from or at risk of developing dry eye syndrome an ocular protective combination (OPC) composition comprising:

Vitamin E B6 Folate Zinc Alpha Lipoic Acid Green Tea Astaxanthin Ginkgo biloba Hops Ouercetin Tocotrienol Complex Bilberry Extract Blueberry Powder Tart Cherry Curcuma longa Root Powder, and N-Acetyl-L-Cysteine.

110. (Previously Amended) A method of alleviating a symptom of ocular inflammation associated with dry eye syndrome, comprising administering to a subject suffering from or at risk of developing dry eye syndrome an ocular protective combination (OPC) composition comprising:

Vitamin A (as Vitamin A Palmitate) Vitamin A (as Beta Carotene) Vitamin C (as Ascorbic Acid)

Vitamin D (as Cholecalciferol)

Vitamin E (as d-alpha Tocopheryl Succinate)

Vitamin E (as Mixed Tocopherols)

Vitamin K

Thiamin (as Thiamine Mononitrate)

Riboflavin

Niacin (as Niacinamide)

Vitamin B6 (as Pyridoxine HC1)

Folate (as Folic Acid)

Vitamin B 12 (as Cyanocobalamin)

Pantothenic Acid (as Calcium Pantothenate)

Biotin

Choline (as Choline Bitartrate)

Chromium (as Chromium nicotinate)

Copper (as Copper Citrate)

Iodine (as Potassium Iodine)

Magnesium (as Magnesium Citrate)

Manganese (as Manganese Citrate)

Selenium (as Selenomathionine)

Zinc (as Zinc Citrate)

Alpha Lipoic Acid

Green Tea (40% Polyphenois)

Bilberry Ext (25% Anthocyanidins)

Blueberry Powder

Ginkgo biloba SE 24/6

Hops PE

Ouercetin

Tocotrienol Complex

Grape Seed Extract

Citrus Bioflavonoids

Taurine

N-Acetyl-L-Cysteine

Curcuma longa Root Powder

Zeaxanthin

Astaxanthin

Mixed Carotenoids

Trace Minerals (Hydromins), and

Tart Cherry Powder.

111. (Previously Amended) A method of alleviating a symptom of ocular inflammation associated with dry eye syndrome, comprising administering to a subject suffering from or at risk of developing dry eye syndrome an ocular protective combination (OPC) composition comprising:

Vitamin A (as Vitamin A Palmitate) Vitamin A (as Beta Carotene) Vitamin C (as Ascorbic Acid) Vitamin E (as d-alpha Tocopheryl Succinate) Vitamin E (as Mixed Tocopherols) B6 (as Pyndoxine HC1) Folate (as Folic Acid) Zinc (as Zinc Citrate) Alpha Lipoic Acid Green Tea (40% polyphenols) Astaxanthin Ginkgo biloba SE 24/6 Hops PE Ouercetin Tocotrienol Complex Bilberry Ext (25% Anthocyanidins) Blueberry Powder Tart Cherry Curcuma longa Root Powder, and N-Acetyl-L-Cysteine.

112. (Previously Amended) A method of alleviating a symptom of ocular inflammation associated with dry eye syndrome, comprising administering to a subject suffering from or at risk of developing dry eye syndrome an ocular protective combination (OPC) composition comprising the ingredients and daily dosages:

| INGREDIENT | DAILY DOSAGE | |
|---|--------------|------|
| Vitamin A (as Vitamin A Palmitate) | 250.00 | IU |
| Vitamin A (as Beta Carotene) | 5000.00 | IU |
| Vitamin C (as Ascorbic Acid) | 300.00 | MG |
| Vitamin D (as Cholecalciferol) | 200.00 | IU |
| Vitamin E (as d-alpha Tocopheryl Succinate) | 100.00 | IU_ |
| Vitamin E (as Mixed Tocopherols) | 50.00 | IU _ |
| Vitamin K | 0.06 | MG |
| Thiamin (as Thiamine Mononitrate) | 120 | MG |
| Riboflavin | 1.30 | MG |
| Niacin (as Niacinamide) | 16.00 | MG |
| Vitamin B6 (as Pyridoxine HCI) | 3.00 | MG |

| | | _ |
|--|-----------|---|
| Folate (as Folic Acid) | 0.40 MC | |
| Vitamin B12 (as Cyanocobalamin) | 0.0024 MC | |
| Pantothenic Acid (as Calcium Pantothenate) | 5.00 MC | |
| Biotin | 0.03 MC | |
| Choline (as Choline Bitartrate) | 275.00 MC | |
| Chromium (as Chromium nicotinate) | 0.10 MC | ì |
| Copper (as Copper Citrate) | 2.00 MC | ì |
| Iodine (as Potassium Iodine) | 0.15 MC | ì |
| Magnesium (as Magnesium Citrate) | 100.00 MC | ì |
| Manganese (as Manganese Citrate) | 2.30 MC | |
| Selenium (as Selenomathionine) | 0.10 MC | ì |
| Zinc (as Zinc Citrate) | 15.00 MC | ì |
| Alpha Lipoic Acid | 30.00 MC | ì |
| Green Tea (40% Polyphenols) | 200.00 MC | ì |
| Bilberry Ext (25% Anthocyanidins) | 4.00 MC | ì |
| Blueberry Powder | 100.00 MC | ì |
| Ginkgo biloba SE 24/6 | 250.00 MC | ì |
| Hops PE | 10.00 MC | ì |
| Quercetin | 50.00 MC | ì |
| Tocotrienol Complex | 50.00 MC | ì |
| Grape Seed Extract | 20.00 MC | ì |
| Citrus Bioflavonoids | 400.00 MC | ì |
| Taunine | 300.00 MC | ì |
| N-Acetyl-L-Cysteine | 200.00 MC | ì |
| Curcuma longa Root Powder | 50.00 MC | ì |
| Zeaxanthin | 1.00 MC | ì |
| Astaxanthin | 1.00 MC | Ĵ |
| Mixed Carotenoids | 50.00 MC | j |
| Trace Minerals (Hydromins) | 50.00 MC | } |
| Tart Cherry Powder | 50.00 MC | ì |

113. (Previously Amended) A method of alleviating a symptom of ocular inflammation associated with dry eye syndrome, comprising administering to a subject suffering from or at risk of developing dry eye syndrome an ocular protective combination (OPC) composition comprising the ingredients and daily dosages:

| INGREDIENT | DAILY DOSAGE | |
|---|--------------|----|
| Vitamin A (as Vitamin A Paimitate) | 250.00 | |
| Vitamin A (as Beta Carotene) | 5000.00 | |
| Vitamin C (as Ascorbic Acid) | 300.00 | MG |
| Vitamin E (as d-alpha Tocopheryl Succinate) | 100.00 | IU |
| Vitamin E (as Mixed Tocopherols) | 50.00 | 1U |

| B6 (as Pyndoxine HCl) | 3.00 MG |
|-----------------------------------|-----------|
| Folate (as Folic Acid) | 0.40 MG |
| Zinc (as Zinc Citrate) | 15.00 MG |
| Alpha Lipoic Acid | 30.00 MG |
| Green Tea (40% polyphenols) | 200.00 MG |
| Astaxanthin | 1.00 MG |
| Ginkgo biloba SE 24/6 | 250.00 MG |
| Hope PE | 10.00 MG |
| Quercetin | 50.00 MG |
| Tocotrienol Complex | 50.00 MG |
| Bilberry Ext (25% Anthocyanidins) | 4.00 MG |
| Blueberry Powder | 50.00 MG |
| Tart Cherry | 50.00 MG |
| Curcuma longa Root Powder | 50.00 MG |
| N-Acetyl-L-Cysteine | 200.00 MG |

114. (Previously presented) The method of claim 108, 109, 110, 111, 112, or 113, wherein said method further comprises co-administering to said subject a composition comprising an omega-3 fatty acid selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid, thereby alleviating said symptom of said dry eye syndrome.